Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Han, Sae Won ^a,b   Cha, Yongjun ^a   Paquet, Agnes ^c   Huang, Weidong ^c   Weidler, Jodi ^c   Lie, Yolanda ^c   Sherwood, Thomas ^c   Bates, Michael ^c   Haddad, Mojgan ^c   Park, In Hae ^d   Oh, Do Youn ^a,b   Lee, Keun Seok ^d   Im, Seock Ah ^a,b   Bang, Yung Jue ^a,b   Ro, Jungsil ^d   Kim, Tae You ^a,b,e  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c MONOGRAM BIOSCIENCES   (United States)

^d National Cancer Center   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LAPATINIB; P95HER2 PROTEIN; RECEPTOR PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; ASSAY; BREAST METASTASIS; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SAMPLE; TIME TO PROGRESSION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SURVIVAL RATE;

EID: 84864398790     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039943     Document Type: Article

References (29)

1. Hsieh AC, Moasser MM, (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97: 453-457.
2. Moasser MM, (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26: 6469-6487.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
8. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595.
9. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, et al. (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628-638.
10. Xia W, Liu LH, Ho P, Spector NL, (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23: 646-653.
11. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, et al. (2010) Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 16: 4226-4235.
12. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743.
13. Lipton A, Kostler WJ, Leitzel K, Ali SM, Sperinde J, et al. (2010) Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 116: 5168-5178.
14. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, et al. (2006) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 25: 118-145.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
16. Shi Y, Huang W, Tan Y, Jin X, Dua R, et al. (2009) A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol 18: 11-21.
17. Larson JS, Goodman LJ, Tan Y, Defazio-Eli L, Paquet AC, et al. (2010) Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens. Patholog Res Int 2010: 814176.
18. Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, et al. (2010) Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol 134: 303-311.
19. Naidu R, Yadav M, Nair S, Kutty MK, (1998) Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78: 1385-1390.
20. Hynes NE, Lane HA, (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
21. Menendez JA, Lupu R, (2007) Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited? Breast Cancer Res 9: 111.
22. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, et al. (1995) Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821.
23. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, et al (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100: 8933-8938.
24. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
25. Motoyama AB, Hynes NE, Lane HA, (2002) The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62: 3151-3158.
26. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, et al. (2004) The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 91: 1190-1194.
27. Goodman LJ, Weston JK, Mukherjee A, Sperinde J, Paquet A, et al. (2009) Quantitative measurement of HER3 total protein (H3T) and association with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. ASCO Meeting Abstracts 27: 1021.
28. Arribas J, Baselga J, Pedersen K, Parra-Palau JL, (2011) p95HER2 and breast cancer. Cancer Res 71: 1515-1519.
29. Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, et al. (2010) Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 16: 2688-2695.